22nd Century Group Inc (NASDAQ:XXII)
| 0.6236 Delayed Data As of 4:00pm ET |  -0.0181 / -2.82%Today’s Change | 0.58 Today|||52-Week Range 2.70 | -32.25% Year-to-Date |
Latest XXII News | Press Releases
No recent news for 22nd Century Group Inc.
Today’s Trading
| Previous close | 0.64 |
| Today’s open | 0.65 |
| Day’s range | 0.61 - 0.67 |
| Volume | 16,281 |
| Average volume (3 months) | 1,075,178 |
| Market cap | $138.5M |
Data as of 4:00pm ET, 05/31/2023
Growth & Valuation
| Earnings growth (last year) | -47.46% |
| Earnings growth (this year) | +10.32% |
| Earnings growth (next 5 years) | +30.00% |
| Revenue growth (last year) | +100.69% |
| P/E ratio | NM |
| Price/Sales | 2.86 |
| Price/Book | 1.40 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| HRTXHeron Therapeutics I... | -0.03 | -2.94% |
| INMBINmune Bio Inc | -0.19 | -2.41% |
| PLXProtalix Biotherapeu... | +0.08 | +3.98% |
| LRMRLarimar Therapeutics... | +0.12 | +3.33% |
Data as of 4:00pm ET, 05/31/2023
Financials
| Next reporting date | August 8, 2023 |
| EPS forecast (this quarter) | -$0.07 |
| Annual revenue (last year) | $62.1M |
| Annual profit (last year) | -$59.8M |
| Net profit margin | -96.28% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters Buffalo, New York |
Forecasts
